Senior jobs at CK Clinical

If you are working at a senior level and are looking for jobs that are exclusive for you, make sure you visit our dedicated page.

CK Clinical recruit for jobs at all levels, working with companies ranging from large global pharmaceuticals through to independent CRO’s. As such our consultants are highly experienced at working with professionals with varying levels of expertise who are looking for their dream job. We work alongside our clients, often running head hunting campaigns, to ensure we find the right person for the right job.

Click here to view our Senior Jobs

 

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , , , , , , , ,

Pharma Companies Solve ClinicalTrial Inefficiencies

As reported by The Pharma Times, ten of the world’s top pharma companies have come together to form Tran

sCelerate BioPharma

, with the aim of combatting inefficiencies in clinical trials.

This is the largest ever initiative of this kind and will involve the following pharmaceutical companies will be involved:

 

Over the past few decades, the productivity of research and development within the pharmaceutical industry has been declining whilst the costs have been steadily rising. In fact, it is estimated that about 5,000 to 10,000 potential drugs fail for every one that is approved. In addition, the cost of getting a drug approved has risen from $140m in the 1970s to over $1.2 billon. One reason for this increase is the time it takes from finding a compound to getting it approved by regulators – which can take between 10 to 15 years.

Therefore, the aim of TransCelerate is to shorten this time whilst reducing costs. This is explained by TransCelerate Head, Gary Neil: “It will enable everybody to develop new drugs faster and better. If this helps to reduce costs, then maybe we can investigate more drugs.”

Looking for a new position in the pharmaceutical industry?

Click here to register your CV with us today.

 

10 Global Pharma Companies Collaborate to Solve Clinical Trial Inefficiencies 10 Global Pharma Companies Collaborate to Solve Clinical Trial Inefficiencies 10 Global Pharma Companies Collaborate to Solve Clinical Trial Inefficiencies 10 Global Pharma Companies Collaborate to Solve Clinical Trial Inefficiencies

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , , , ,

Icon plans to open a Translational Medicine Research Centre in Manchester

Pharmatimes has reported that Icon has announced plans to further expand its UK hospital-based presence on the Manchester Royal Infirmary Campus by opening a Translational Medicine Research Centre.

ICON has secured a 40,000 square foot pre-let at Citylabs, a newly developed biomedical centre of excellence which was formerly the Manchester Royal Eye Hospital. This new centre will also host biohealth organisations including the Central Manchester University Hospitals NHS Foundation Trust, The University of Manchester, and other commercial research enterprises.

ICON currently operates a hospital-based Clinical Pharmacology Unit on the Manchester Royal Infirmary Campus, where it will continue to run it’s Phase I operations until fully transitioning to the new, larger Citylabs facility, which is scheduled to open in the fourth quarter of 2013.

“We are pleased to be expanding our early phase development services through the establishment of a Centre of Excellence for Translational Medicine in Citylabs,” commented Dr. Mario Rocci, President, ICON Development Solutions. “This expansion will enable ICON to increase the capacity of its Clinical Pharmacology Unit in Manchester as well as the scientific services that are essential in providing a world class offering.”

 

Are you looking for a new job in the clinical industry?

 Click here to see our latest clinical jobs

          

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , ,

AstraZeneca & Assay Depot launch virtual laboratory

Pharmatimes have reported that Astra Zeneca and Assay Depot have launched a new virtual laboratory which will allow the scientist to work from a laptop.

Assay Depot can be compared to Amazon.com but for industry and academic drug researchers looking to tap into research services from drug discovery through to clinical trials.

It offers a single, secure, cloud-based location where researchers can compare service descriptions, view customer reviews, request quotes, place orders, track service progress and retrieve data reports.

The private virtual research laboratory developed by Assay Depot in partnership with AstraZeneca is effectively a vendor relationship-management system with easy access to a network of “thousands” of research-service providers both inside and outside the company.

Mike Snowden, the Astra Zeneca’s vice president of discovery sciences said “We look forward to assessing how the virtual laboratory platform impacts and accelerates productivity in the R&D pipeline,”

 

Are you looking for a new role in the pharmaceutical industry?

Click here to see our latest pharmaceutical roles

Posted in Industry News, NewsTagged in , , , , , , , , , , , , ,

Clinical jobs in the UK and Europe

Jim Gleeson at CK Clinical is currently recruiting for a number of clinical based positions in Europe and the UK:

Please click on the links below to find out more and apply:

 

Associate Clinical Project Manager, Munich

Senior CRA, Home Based, UK

Clinical Administration Assistant

 

Register your CV at CK Clinical

Click here to register your CV online now >

Posted in Featured Jobs, NewsTagged in , , , , , , , , , , , , , , , , ,

Free flu vaccinations for all children in the UK using AZ’s Fluenz

The BBC has reported that the UK government have announced that children between the ages of two to 17-year-olds in the UK are to be offered annual flu vaccinations free of charge.

This will be the first initiative of its kind in the world and the Joint Committee on Vaccination and Immunisation (JCVI) believes even with moderate vaccination uptake among children of around 30% there will be 11,000 fewer hospitalisations and 2,000 fewer deaths each year. The children will be immunised using a nasal spray rather than an injection, starting in 2014 at the earliest.

The news is particularly good for AstraZeneca, as the JCVI has advised that its live attenuated intranasal influenza vaccine Fluenz should be the vaccine of choice for extending the programme, “given the evidence of effectiveness, protection against drifted strains and safety, and in the absence of any equivalently effective alternative authorised vaccine”.

 

Are you looking for a new job in the clinical industry?

 Click here to see our latest clinical jobs

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , ,

Australian scientists make IVF discovery

The Telegraph has reported that a study of more than 50,000 births in Australia and New Zealand found the death rate of babies conceived using in-vitro fertilisation is significantly reduced when only one embryo is implanted.

The study found the difference was more pronounced in births involving fresh rather than frozen embryos. Births involving two fresh embryos had a 74 per cent higher risk of perinatal mortality than births following fresh single transfers.

The study leader, Elizabeth Sullivan, said the findings showed that Australia’s policy of promoting single embryo implants had helped to reduce infant mortality rates.   Countries such as the United States and the United Kingdom have rates of single embryo transfers of between 12 and 15 per cent, compared with 70 per cent in Australia.

 

Are you looking for a new role in clinical research? Click here to see our latest clinical research jobs?

Posted in company news, NewsTagged in , , , , , , , , , , , , , ,

Biogen and Isis Team Together in Rare Disease Pact

PharmaTimes reported that Biogen Idec and Isis Pharmaceuticals are forming a partnership to develop an antisense drug for muscular dystrophy in adults (DM1)

Muscular Dystrophy is estimated to affect 150,000 patients in the USA, Europe and Japan and is passed from parent to child with each subsequent generation experiencing more severe disease earlier in life.

Isis will be responsible for the discovery of a lead antisense drug candidate targeting DMPK for the treatment of DM1 (muscular dystrophy in adults)

Steven Holtzman, head of corporate development at Biogen said that “the unmet need is great and there are currently no therapies to slow or stop progression of the disease” He also said DM1 has “an identifiable genetic cause, the program fits with our mission to bring innovative therapies to patients with serious neurologic diseases, and Isis’ antisense compound has the potential to make a real difference”

 

Are you looking for a new clinical job? Click here to see our latest clinical jobs

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

 

 

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , , , , ,

Astellas and DNDi work on tropical disease research

Pharma Times has reported that Astellas Pharmaceuticals has announced an agreement with the Drugs for Neglected Diseases initiative (DNDi) to collaborate on drug discovery research for three neglected tropical diseases

The 3 neglected tropical diseases are leishmaniasis, Chagas disease and sleeping sickness. These 3 together affect nearly 10 million people worldwide

Under the agreement, Astellas will provide DNDi with a selection of original compounds. These will be screened at the Swiss Tropical and Public Health Institute in Switzerland

Executive Director of DNDi, Dr Bernard Pécoul, said “We welcome Astellas as a new partner both in the field of NTDs and as part of a product development partnership. In the field of neglected diseases, and particularly for the most neglected – leishmaniasis, Chagas disease, and sleeping sickness – this new partnership reinforces the critical mass of engaged actors necessary to address urgent patient needs”

Are you looking for a new clinical job? Click here to see our latest clinical jobs

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , ,

GSK increases ownership in Theravance

As reported by Pharmiweb, GSK announced today that they have increased their shares in Theravance, who they have a long standing partnership with.

Theravance’s shareholders have approved the transaction which will see the UK drug major buy 10 million shares priced at $21.29 apiece. This means GSK now owns about 25.8 million shares in  Theravance’s.

The companies have been partners for nearly ten years and have developed Relovair, which combines a once-daily inhaled corticosteroid (fluticasone) with a long-acting beta-agonist (vilanterol). Phase III development has been completed and GSK intends to submit regulatory applications for chronic obstructive pulmonary disease in the USA and Europe in mid-2012.

Click here to see our latest jobs in clincial research

Also click here to see our Clinical Research Nurse jobs at the Salford Lung Study

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

Posted in Industry News, NewsTagged in , , , , , , , , , , , , ,